Cyclo Therapeutics (Nasdaq:CYTH) - Cotización, noticias y análisis

Resumen de acción CYTH

Cyclo Therapeutics, Inc, empresa biotecnológica en fase clínica, se dedica al desarrollo de productos basados en ciclodextrinas para el tratamiento de enfermedades neurodegenerativas. Saber más

Análisis fundamental de CYTH
Puntuación del snowflake
Valoración	0/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	0/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 75.33%

Análisis de riesgos

Patrimonio neto negativo

Tiene menos de 1 año de cash runway

Tiene unos ingresos inferiores a 1 millón de dólares ($871K)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

+ 3 riesgos adicionales

Competidores de Cyclo Therapeutics, Inc.

Zeo ScientifiX

OTCPK:ZEOX

US$20.4m

Pieris Pharmaceuticals

NasdaqCM:PIRS

US$21.1m

OpGen

OTCPK:OPGN

US$15.1m

Vascular Biogenics

NasdaqCM:VBLT

US$12.1m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Cyclo Therapeutics
Precios históricos de las acciones
Precio actual de la acción	US$0.73
Máximo en las últimas 52 semanas	US$2.12
Mínimo de 52 semanas	US$0.59
Beta	-0.38
1Cambio en 1 mes	-2.67%
Variación en 3 meses	-6.41%
Cambio de 1 año	-43.41%
3Variación en 3 años	-86.17%
Variación en 5 años	-97.19%
Variación desde la OPV	-99.63%

Noticias y actualizaciones recientes

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Rentabilidad de los accionistas

	CYTH	US Biotechs	Mercado US
7D	4.4%	2.4%	2.2%
1Y	-43.4%	16.2%	31.7%

Rentabilidad vs. Industria: Los resultados de CYTH fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 16.2% el año pasado.

Rentabilidad vs. Mercado: CYTH obtuvo unos resultados inferiores a los del mercado US, que fueron del 31.7% el año pasado.

Volatilidad de los precios

Is CYTH's price volatile compared to industry and market?
CYTH volatility
CYTH Average Weekly Movement	10.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: El precio de las acciones de CYTH ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CYTH(10%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1990	8	N. Fine	cyclotherapeutics.com

Cyclo Therapeutics, Inc, empresa de biotecnología en fase clínica, se dedica al desarrollo de productos a base de ciclodextrina para el tratamiento de enfermedades neurodegenerativas. El principal candidato a fármaco de la empresa es Trappsol Cyclo (hidroxipropil beta ciclodextrina), un medicamento huérfano, que se encuentra en ensayos clínicos de fase III para el tratamiento de la enfermedad de Niemann-Pick tipo C; y en ensayos clínicos de fase IIb para el tratamiento de la enfermedad de Alzheimer. También vende ciclodextrinas y productos relacionados a las industrias farmacéutica, nutricional y otras, principalmente para su uso en diagnósticos y medicamentos especializados.

Resumen de fundamentos de Cyclo Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Cyclo Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de CYTH
Capitalización bursátil	US$20.11m
Beneficios(TTM)	-US$24.80m
Ingresos (TTM)	US$870.73k

24.1x

Ratio precio-ventas (PS)

-0.8x

Ratio precio-beneficio (PE)

¿Está CYTH sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CYTH
Ingresos	US$870.73k
Coste de los ingresos	US$76.25k
Beneficio bruto	US$794.48k
Otros gastos	US$25.59m
Beneficios	-US$24.80m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.86
Margen bruto	91.24%
Margen de beneficio neto	-2,848.16%
Ratio deuda/patrimonio	-90.4%

¿Cómo se ha desempeñado CYTH a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción CYTH

Recompensas

Análisis de riesgos

Competidores de Cyclo Therapeutics, Inc.

OTCPK:ZEOX

US$20.4m

NasdaqCM:PIRS

US$21.1m

OTCPK:OPGN

US$15.1m

NasdaqCM:VBLT

US$12.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New major risk - Financial position

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics Receives Two Letters from Nasdaq Due to Non-Compliance with Multiple Nasdaq Listing Rules

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

Recent updates

New major risk - Financial position

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics Receives Two Letters from Nasdaq Due to Non-Compliance with Multiple Nasdaq Listing Rules

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo